Insulin aspart

Drug Profile

Insulin aspart

Alternative Names: Asp-B28; NovoLog; NovoRapid

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator ZymoGenetics
  • Developer Novo Nordisk
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gestational diabetes; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 16 Sep 2016 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of insulin aspart for Type-1 diabetes mellitus (In adolescents, In children) in European Union
  • 03 Nov 2014 NovoRapid® PumpCart® prefilled pump cartridge has been launched in the United Kingdom, Austria and Sweden
  • 22 Nov 2013 Committee for Medicinal Products for Human Use (CHMP) recommends approval of insulin aspart prefilled pump cartridge, NovoRapid® PumpCart®, in the EU
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top